These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 2829914)
1. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. van Meel JC; Zimmermann R; Diederen W; Erdman E; Mrwa U Biochem Pharmacol; 1988 Jan; 37(2):213-20. PubMed ID: 2829914 [TBL] [Abstract][Full Text] [Related]
2. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153 [TBL] [Abstract][Full Text] [Related]
3. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. Lues I; Beier N; Jonas R; Klockow M; Haeusler G J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712 [TBL] [Abstract][Full Text] [Related]
4. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase. Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951 [TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties. Holck M; Thorens S; Muggli R; Eigenmann R J Cardiovasc Pharmacol; 1984; 6(3):520-30. PubMed ID: 6202981 [TBL] [Abstract][Full Text] [Related]
6. Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart. Meyer W; Nose M; Schmitz W; Scholz H Naunyn Schmiedebergs Arch Pharmacol; 1984 Dec; 328(2):207-9. PubMed ID: 6098837 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations. Akahane K; Furukawa Y; Haniuda M; Karasawa Y; Chiba S Jpn Heart J; 1989 Nov; 30(6):903-15. PubMed ID: 2561162 [TBL] [Abstract][Full Text] [Related]
8. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues. Davey DD; Erhardt PW; Cantor EH; Greenberg SS; Ingebretsen WR; Wiggins J J Med Chem; 1991 Sep; 34(9):2671-7. PubMed ID: 1654425 [TBL] [Abstract][Full Text] [Related]
10. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359 [TBL] [Abstract][Full Text] [Related]
11. Intracellular Na+ activity and positive inotropic effect of sulmazole in guinea pig ventricular myocardium. Comparison with a cardioactive steroid. Schmied R; Wang GX; Korth M Circ Res; 1991 Feb; 68(2):597-604. PubMed ID: 1991358 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Stehlik J; Movsesian MA Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138 [TBL] [Abstract][Full Text] [Related]
14. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Ahn HS; Eardley D; Watkins R; Prioli N Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728 [TBL] [Abstract][Full Text] [Related]
15. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Endoh M; Yanagisawa T; Taira N; Blinks JR Circulation; 1986 Mar; 73(3 Pt 2):III117-33. PubMed ID: 2417745 [TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium. Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013 [TBL] [Abstract][Full Text] [Related]
17. Imidazopyridines: roles of pyridine nitrogen position and methylsulfinyl oxygen for in vitro positive inotropic mechanism and chronotropic activity. Honerjäger P; Klockow M; Schönsteiner G; Jonas R J Cardiovasc Pharmacol; 1989 May; 13(5):673-81. PubMed ID: 2472514 [TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. Coates WJ; Connolly B; Dhanak D; Flynn ST; Worby A J Med Chem; 1993 May; 36(10):1387-92. PubMed ID: 8388468 [TBL] [Abstract][Full Text] [Related]
20. A comparative study of the cardiovascular and biochemical actions of the imidazo [4,5b] pyridine sulmazole and an imidazo [4,5c] pyridine analogue, BW A746C. Allan G; Cambridge D; Follenfant MJ; Stone D; Whiting MV Br J Pharmacol; 1988 Feb; 93(2):387-98. PubMed ID: 3359112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]